Instructions for Farxiga (Dapagliflozin) 10 mg 30 pills
English product name
Farxiga
Release form
tabletop coated with film sheath, 5 mg: 30 pcs
tabletop coated with film sheath, 10 mg: 30 pcs
Description
The tablets are covered with a yellow film shell, diamond-shaped, double-convex, with an engraving of "10" on one side and "1428" on the other side.
1 tab.
Dapagliflozin propanediol monohydrate 12.3 mg,
which corresponds to the content of Dapagliflozin 10 mg
Auxiliary substances: cellulose microcrystalline - 171.45 mg, lactose anhydrous - 50 mg, crospovidone - 10 mg, silicon dioxide - 3.75 mg, magnesium stearate - 2.5 mg.
Shell Composition:
Opadray® II yellow - 10 mg (polyvinyl alcohol partially hydrolyzed - 4 mg,
titanium dioxide - 2.35 mg,
macrogol 3350 - 2.02 mg,
talc - 1.48 mg,
iron oxide yellow - 0.15 mg).
10 pcs - perforated aluminium foil blisters (3) - cardboard packs with first opening control.
ATC codes
A10BK01 Dapagliflozin
Clinical-pharmacological groups / Group affiliation
Oral hypoglycemic preparation is an inhibitor of a sodium-dependent glucose carrier of the second type
Active substance
Dapagliflozin
Pharmacotherapy group
Hypoglycemic agent for peroral administration is an inhibitor of a sodium-dependent glucose transporter type 2
Storage Conditions
The drug Dapagliflozin should be stored in a place inaccessible to children at a temperature not higher than 30 ° C.
Best before date
The shelf life is three years. Do not apply after the expiry date indicated on the package.
Testimony Farxiga:
- Type 2 diabetes
- Type 2 diabetes in adult patients in addition to diet and exercise to improve glycemic control as:
- monotherapy, when metformin is not available due to intolerance;
- combination therapy with metformin, sulfonyl urea derivatives (including in combination with metformin),
- thiazolidindiones, dipeptidyl peptidase inhibitors 4 (DPP-4) (including in combination with metformin),
- gluconic-like polypeptide-1 receptor agonist exenatide with prolonged action in combination with metformin
- insulin preparations (including in combination with one or two hypoglycemic preparations for oral administration) in the
- absence of adequate glycemic control on metformin This therapy;
- starting combination therapy with metformin, if necessary.
- Type II diabetes in adults diagnosed with cardiovascular disease or two or more cardiovascular risk factors* to reduce the
- risk of hospitalization for heart failure.
- Heart failure (II-IV functional class NYHA) with reduced ejection fraction in adult patients to reduce the risk of
- cardiovascular death and hospitalization for heart failure.
Application for kidney disorders Farxiga
The use of the preparation is contraindicated in the event of a disorder in the kidney function at a pSCF which is consistently less than 45 ml/min/1.73 m2, including a serious kidney dysfunction and terminal stage of renal insufficiency, when administered according to indications of CD2; Severe kidney dysfunction and terminal stage renal failure (rSCF less than 30 ml/min/1.73 m2) for indications of heart failure (due to limited experience in clinical trials).
Use in liver disorders
With caution, you should prescribe the drug Dapagliflozin for severe liver failure.
Terms of Sale
The drug is prescription.
Application in elderly patients Dapagliflozin
In elderly patients there is no need to adjust the dose of the drug Dapagliflozin.
Use in children
The use of the preparation in patients under the age of 18 is contraindicated.
- Nosology (ICD codes)
- E11
- Type 2 diabetes
- I50.0
- Congestive heart failure
Method of use, course and dosage Farxiga:
The drug is taken inside, regardless of the ingestion, without chewing.
SD2
Monotherapy: the recommended dose of Farxiga is 10 mg once/day.
Combination therapy: The recommended dose of Farxiga is 10 mg once/day in combination with metformin, sulfonyl urea derivatives (including metformin), thiazolidindyons, DPP-4 inhibitors (including in combination with metformin), GPP-1 receptor agonist prolonged expenatide (in combination with metformin), insulin preparations (including in combination with one or two hypoglycemic oral preparations).
In order to reduce the risk of hypoglycemia, a reduction in the dose of insulin or insulin secretion-enhancing drugs (e.g. sulfonyl urea derivatives) may be required for the co-administration of Farxiga
Starter combination therapy with metformin: the recommended dose of Forsig is ten mg once a day, and the dose of metformin is 500 mg once a day. In the case of inadequate glycemic control, the metformin dose should be increased.
CD2 in adults diagnosed with cardiovascular disease or two or more cardiovascular risk factors to reduce the risk of hospitalization for heart failure: the recommended dose of Farxiga is 10 mg once a day.
